Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:2531
Name hematologic cancer
Definition An organ system cancer located in the hematological system that is characterized by uncontrolled cellular proliferation in blood, bone marrow and lymph nodes.
Source DiseaseOntology.org
Alt Ids DOID:2532 DOID:1034
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
PIK3CA mutant CUDC-907 hematologic cancer sensitive detail...
JAK2 V617F JAK2 E864K NVP-BSK805 hematologic cancer resistant detail...
JAK2 V617F JAK2 E864K NVP-BVB808 hematologic cancer resistant detail...
JAK2 V617F JAK2 E985K Ruxolitinib hematologic cancer resistant detail...
JAK2 V617F JAK2 G935R Ruxolitinib hematologic cancer resistant detail...
JAK2 V617F JAK2 G935R NVP-BSK805 hematologic cancer resistant detail...
JAK2 V617F JAK2 G935R NVP-BVB808 hematologic cancer resistant detail...
JAK2 V617F JAK2 I960V Ruxolitinib hematologic cancer resistant detail...
JAK2 V617F JAK2 I960V Lestaurtinib hematologic cancer resistant detail...
JAK2 V617F JAK2 I960V Fedratinib hematologic cancer resistant detail...
JAK2 V617F JAK2 I960V AZD1480 hematologic cancer resistant detail...
JAK2 V617F JAK2 I960V Momelotinib hematologic cancer resistant detail...
JAK2 V617F JAK2 M929I Ruxolitinib hematologic cancer resistant detail...
JAK2 V617F JAK2 R938L Ruxolitinib hematologic cancer resistant detail...
JAK2 V617F JAK2 R938L Momelotinib hematologic cancer resistant detail...
JAK2 V617F JAK2 R938L Lestaurtinib hematologic cancer resistant detail...
JAK2 V617F JAK2 R938L Fedratinib hematologic cancer resistant detail...
JAK2 V617F JAK2 R938L AZD1480 hematologic cancer resistant detail...
FBXW7 inact mut Belinostat hematologic cancer sensitive detail...
FBXW7 inact mut AR-42 hematologic cancer sensitive detail...
KIT D816V Sorafenib hematologic cancer resistant detail...
KIT D816V Imatinib hematologic cancer resistant detail...
IDH2 mutant Enasidenib hematologic cancer sensitive detail...
FBXW7 inact mut Entinostat hematologic cancer sensitive detail...
JAK2 R867Q Fedratinib hematologic cancer decreased response detail...
JAK2 R867Q Ruxolitinib hematologic cancer decreased response detail...
JAK2 R867Q AZ960 hematologic cancer decreased response detail...
JAK2 R867Q Momelotinib hematologic cancer decreased response detail...
JAK2 R867Q Luminespib hematologic cancer decreased response detail...
JAK2 V617F SHP099 hematologic cancer sensitive detail...
NRAS mutant SHP099 hematologic cancer predicted - resistant detail...
BRAF K601N LY3009120 hematologic cancer sensitive detail...
JAK2 V617F Ilginatinib hematologic cancer sensitive detail...
FLT3 exon 14 ins FLT3 N676D SKI-G-801 hematologic cancer sensitive detail...
FLT3 exon 14 ins FLT3 F691L SKI-G-801 hematologic cancer sensitive detail...
FLT3 D835Y SKI-G-801 hematologic cancer sensitive detail...
FLT3 N676D FLT3 D835Y SKI-G-801 hematologic cancer sensitive detail...
FLT3 exon 14 ins GTP-14564 hematologic cancer sensitive detail...
JAK2 V617F BMS-911543 hematologic cancer sensitive detail...
FGFR1 fusion Derazantinib hematologic cancer sensitive detail...
KIT D816V FF-10101 hematologic cancer sensitive detail...
FLT3 exon 14 ins FLT3 Y842C FF-10101 hematologic cancer sensitive detail...
FLT3 exon 14 ins FLT3 Y842H FF-10101 hematologic cancer sensitive detail...
JAK3 A573V Tofacitinib hematologic cancer sensitive detail...
JAK3 M511I Tofacitinib hematologic cancer sensitive detail...
JAK3 H583Y Tofacitinib hematologic cancer sensitive detail...
JAK3 G589D Tofacitinib hematologic cancer sensitive detail...
FLT3 D835Y Crenolanib hematologic cancer sensitive detail...
FLT3 Y572C Crenolanib hematologic cancer sensitive detail...
FLT3 K429E Crenolanib hematologic cancer resistant detail...
FLT3 F691L FLT3 D835Y Crenolanib hematologic cancer resistant detail...
FLT3 D200N FLT3 D835Y Crenolanib hematologic cancer sensitive detail...
FLT3 L601F FLT3 D835Y Crenolanib hematologic cancer sensitive detail...
FLT3 D835Y Crenolanib + Trametinib hematologic cancer sensitive detail...
FLT3 D835Y IDH1 wild-type AGI-5198 hematologic cancer resistant detail...
FLT3 D835Y IDH1 R132H AGI-5198 hematologic cancer resistant detail...
FLT3 D835Y IDH1 R132H Crenolanib hematologic cancer sensitive detail...
FLT3 D835Y IDH1 wild-type Crenolanib hematologic cancer sensitive detail...
FLT3 D835Y IDH1 R132H AGI-5198 + Crenolanib hematologic cancer sensitive detail...
FLT3 D835Y IDH1 wild-type AGI-5198 + Crenolanib hematologic cancer sensitive detail...
FLT3 exon 14 ins Crenolanib hematologic cancer sensitive detail...
FLT3 exon 14 ins Quizartinib hematologic cancer sensitive detail...
FLT3 exon 14 ins Gilteritinib hematologic cancer sensitive detail...
FLT3 exon 14 ins Midostaurin hematologic cancer sensitive detail...
FLT3 exon 14 ins Sorafenib hematologic cancer sensitive detail...
FLT3 exon 14 ins FLT3 F691L Crenolanib hematologic cancer decreased response detail...
FLT3 exon 14 ins FLT3 F691L Quizartinib hematologic cancer decreased response detail...
FLT3 exon 14 ins FLT3 F691L Gilteritinib hematologic cancer sensitive detail...
FLT3 exon 14 ins FLT3 F691L Midostaurin hematologic cancer sensitive detail...
FLT3 exon 14 ins FLT3 F691L Sorafenib hematologic cancer resistant detail...
FLT3 exon 14 ins FLT3 F691L Avapritinib hematologic cancer decreased response detail...
FLT3 D835Y Quizartinib hematologic cancer sensitive detail...
FLT3 D835Y Gilteritinib hematologic cancer sensitive detail...
FLT3 D835Y Midostaurin hematologic cancer sensitive detail...
FLT3 D835Y Sorafenib hematologic cancer resistant detail...
FLT3 D835Y Avapritinib hematologic cancer resistant detail...
FLT3 exon 14 ins Avapritinib hematologic cancer decreased response detail...
KIT D816V Crenolanib hematologic cancer sensitive detail...
KIT D816V Midostaurin hematologic cancer sensitive detail...
KIT D816V Avapritinib hematologic cancer sensitive detail...
KIT D816V Quizartinib hematologic cancer resistant detail...
KIT D816V Gilteritinib hematologic cancer predicted - sensitive detail...
CBL Q365_E366insSK FLT3 wild-type Crenolanib hematologic cancer sensitive detail...
CBL Q365_E366insSK FLT3 wild-type Quizartinib hematologic cancer sensitive detail...
CBL Q365_E366insSK FLT3 wild-type Gilteritinib hematologic cancer sensitive detail...
CBL Q365_E366insSK FLT3 wild-type Midostaurin hematologic cancer sensitive detail...
CBL Q365_E366insSK FLT3 wild-type Sorafenib hematologic cancer sensitive detail...
CBL Q365_E366insSK FLT3 wild-type Avapritinib hematologic cancer decreased response detail...
CBL Y371H FLT3 wild-type Avapritinib hematologic cancer decreased response detail...
CBL Y371H FLT3 wild-type Crenolanib hematologic cancer sensitive detail...
CBL Y371H FLT3 wild-type Quizartinib hematologic cancer sensitive detail...
CBL Y371H FLT3 wild-type Gilteritinib hematologic cancer sensitive detail...
CBL Y371H FLT3 wild-type Midostaurin hematologic cancer sensitive detail...
CBL Y371H FLT3 wild-type Sorafenib hematologic cancer sensitive detail...
CSF3R T618I Dasatinib hematologic cancer predicted - resistant detail...
CSF3R Q741* AZD1480 hematologic cancer predicted - sensitive detail...
CSF3R W791* AZD1480 hematologic cancer predicted - sensitive detail...
CSF3R T618I CSF3R Q741* AZD1480 hematologic cancer predicted - resistant detail...
CSF3R T618I CSF3R W791* AZD1480 hematologic cancer predicted - resistant detail...
CSF3R T618I CSF3R W791* Ruxolitinib hematologic cancer predicted - resistant detail...
CSF3R T618I CSF3R W791* Dasatinib hematologic cancer predicted - resistant detail...
CSF3R T618I CSF3R Q741* Ruxolitinib hematologic cancer predicted - resistant detail...
CSF3R T618I CSF3R Q741* Dasatinib hematologic cancer predicted - resistant detail...
CSF3R Q741* Ruxolitinib hematologic cancer predicted - sensitive detail...
CSF3R W791* Ruxolitinib hematologic cancer predicted - sensitive detail...
CSF3R Q741* Dasatinib hematologic cancer predicted - resistant detail...
CSF3R W791* Dasatinib hematologic cancer predicted - resistant detail...
JAK2 L583_A586delinsS Ruxolitinib hematologic cancer resistant detail...
JAK2 L583_A586delinsS Momelotinib hematologic cancer resistant detail...
CBL Q365_E366insSK FLT3 pos Sorafenib hematologic cancer sensitive detail...
CBL Q365_E366insSK FLT3 pos Gilteritinib hematologic cancer sensitive detail...
CBL Q365_E366insSK FLT3 pos Crenolanib hematologic cancer sensitive detail...
CBL Q365_E366insSK FLT3 pos Quizartinib hematologic cancer sensitive detail...
CBL Q365_E366insSK FLT3 pos Midostaurin hematologic cancer sensitive detail...
CBL Y371H FLT3 pos Midostaurin hematologic cancer sensitive detail...
CBL Y371H FLT3 pos Sorafenib hematologic cancer sensitive detail...
CBL Y371H FLT3 pos Gilteritinib hematologic cancer sensitive detail...
CBL Y371H FLT3 pos Crenolanib hematologic cancer sensitive detail...
CBL Y371H FLT3 pos Quizartinib hematologic cancer sensitive detail...
CBL Y371del FLT3 pos Quizartinib hematologic cancer sensitive detail...
CBL Y371del FLT3 pos Sorafenib hematologic cancer sensitive detail...
CBL Y371del FLT3 pos Gilteritinib hematologic cancer sensitive detail...
CBL Y371del FLT3 pos Crenolanib hematologic cancer sensitive detail...
CBL Y371del FLT3 pos Midostaurin hematologic cancer sensitive detail...
CBL Y371del FLT3 pos Midostaurin + PRT062607 hematologic cancer sensitive detail...
CBL Y371H FLT3 pos Midostaurin + PRT062607 hematologic cancer sensitive detail...
CBL Q365_E366insSK FLT3 pos Midostaurin + PRT062607 hematologic cancer sensitive detail...
CBL Q365_E366insSK FLT3 pos PRT062607 + Sorafenib hematologic cancer sensitive detail...
CBL Q365_E366insSK FLT3 pos PRT062607 + Quizartinib hematologic cancer sensitive detail...
CBL Y371H FLT3 pos PRT062607 + Quizartinib hematologic cancer sensitive detail...
CBL Y371H FLT3 pos PRT062607 + Sorafenib hematologic cancer sensitive detail...
CBL Q365_E366insSK FLT3 pos Crenolanib + PRT062607 hematologic cancer sensitive detail...
CBL Q365_E366insSK FLT3 pos Gilteritinib + PRT062607 hematologic cancer sensitive detail...
CBL Q365_E366insSK FLT3 pos Entospletinib + Midostaurin hematologic cancer sensitive detail...
JAK2 V617F JAK2 Y931C Ruxolitinib hematologic cancer resistant detail...
JAK2 V617F JAK2 G935R Momelotinib hematologic cancer resistant detail...
JAK2 V617F JAK2 Y931C Momelotinib hematologic cancer resistant detail...
JAK2 V617F JAK2 Y931C AZD1480 hematologic cancer resistant detail...
JAK2 V617F JAK2 G935R AZD1480 hematologic cancer resistant detail...
JAK2 V617F JAK2 Y931C Lestaurtinib hematologic cancer resistant detail...
JAK2 V617F JAK2 G935R Lestaurtinib hematologic cancer resistant detail...
JAK2 V617F JAK2 G935R Fedratinib hematologic cancer resistant detail...
JAK2 V617F JAK2 Y931C Fedratinib hematologic cancer resistant detail...
JAK2 V617F JAK2 E985K Momelotinib hematologic cancer resistant detail...
JAK2 V617F JAK2 E985K Fedratinib hematologic cancer resistant detail...
JAK2 V617F JAK2 E985K AZD1480 hematologic cancer resistant detail...
JAK2 V617F JAK2 E985K Lestaurtinib hematologic cancer resistant detail...
JAK2 V617F JAK2 M929I Momelotinib hematologic cancer predicted - sensitive detail...
JAK2 V617F JAK2 M929I Fedratinib hematologic cancer predicted - sensitive detail...
JAK2 V617F JAK2 M929I AZD1480 hematologic cancer predicted - sensitive detail...
JAK2 V617F JAK2 M929I Lestaurtinib hematologic cancer predicted - sensitive detail...
KIT N822K Crenolanib hematologic cancer sensitive detail...
KIT N822K Dasatinib hematologic cancer sensitive detail...
KIT D816V Dasatinib hematologic cancer sensitive detail...
KIT D419del Crenolanib hematologic cancer no benefit detail...
KIT D419del Dasatinib hematologic cancer no benefit detail...
KIT D419G Crenolanib hematologic cancer no benefit detail...
KIT D419G Dasatinib hematologic cancer no benefit detail...
FLT3 exon 14 ins FLT3 D835Y Palbociclib hematologic cancer no benefit detail...
FLT3 D835Y Palbociclib hematologic cancer sensitive detail...
FLT3 exon 14 ins Palbociclib hematologic cancer sensitive detail...
FLT3 D835Y Danusertib + Palbociclib hematologic cancer sensitive detail...
FLT3 exon 14 ins FLT3 D835Y Danusertib + Palbociclib hematologic cancer no benefit detail...
FLT3 D835Y Alisertib + Palbociclib hematologic cancer sensitive detail...
FLT3 D835Y Everolimus + Palbociclib hematologic cancer sensitive detail...
JAK3 M511I Ruxolitinib hematologic cancer sensitive detail...
JAK3 M511I Baricitinib hematologic cancer sensitive detail...
JAK3 M511I Decernotinib hematologic cancer sensitive detail...
JAK3 M511I ASP015K hematologic cancer sensitive detail...
JAK3 L857Q Ruxolitinib hematologic cancer sensitive detail...
JAK3 L857Q Tofacitinib hematologic cancer sensitive detail...
JAK3 L857Q Baricitinib hematologic cancer sensitive detail...
JAK3 L857Q Decernotinib hematologic cancer sensitive detail...
JAK3 L857Q ASP015K hematologic cancer sensitive detail...
JAK3 L875H Ruxolitinib hematologic cancer predicted - sensitive detail...
JAK3 L875H Tofacitinib hematologic cancer predicted - sensitive detail...
JAK3 L875H Baricitinib hematologic cancer resistant detail...
JAK3 L875H Decernotinib hematologic cancer predicted - sensitive detail...
JAK3 L875H ASP015K hematologic cancer predicted - sensitive detail...
JAK3 L857Q Upadacitinib hematologic cancer sensitive detail...
JAK3 L857H Upadacitinib hematologic cancer resistant detail...
ALK A348D Crizotinib hematologic cancer sensitive detail...
ALK A348D TAE684 hematologic cancer sensitive detail...
ALK A348D Brigatinib hematologic cancer sensitive detail...
ALK A348D Ceritinib hematologic cancer sensitive detail...
ALK F856S GSK1838705A hematologic cancer sensitive detail...
ALK F856S Crizotinib hematologic cancer sensitive detail...
ALK A348D GSK1838705A hematologic cancer sensitive detail...
ALK F856S TAE684 hematologic cancer sensitive detail...
ALK F856S Brigatinib hematologic cancer sensitive detail...
ALK F856S Ceritinib hematologic cancer sensitive detail...
FLT3 exon 14 ins FLT3 D835N HQP1351 hematologic cancer sensitive detail...
FLT3 exon 14 ins FLT3 F691I HQP1351 hematologic cancer sensitive detail...
FLT3 exon 14 ins FLT3 G697R HQP1351 hematologic cancer sensitive detail...
FLT3 exon 14 ins FLT3 Y842H HQP1351 hematologic cancer sensitive detail...
FLT3 exon 14 ins FLT3 Y842R HQP1351 hematologic cancer sensitive detail...
FLT3 exon 14 ins FLT3 D835G HQP1351 hematologic cancer sensitive detail...
FLT3 exon 14 ins FLT3 D835A HQP1351 hematologic cancer sensitive detail...
FLT3 exon 14 ins FLT3 N676D HQP1351 hematologic cancer sensitive detail...
FLT3 exon 14 ins HQP1351 hematologic cancer sensitive detail...
FLT3 D835Y HQP1351 hematologic cancer sensitive detail...
FLT3 D835H HQP1351 hematologic cancer predicted - sensitive detail...
FLT3 D835V HQP1351 hematologic cancer predicted - sensitive detail...
FLT3 R834Q HQP1351 hematologic cancer predicted - sensitive detail...
FLT3 exon 14 ins FLT3 D835Y HQP1351 hematologic cancer predicted - sensitive detail...
FLT3 exon 14 ins FLT3 D835V HQP1351 hematologic cancer predicted - sensitive detail...
FLT3 exon 14 ins FLT3 D835I HQP1351 hematologic cancer predicted - sensitive detail...
FLT3 exon 14 ins FLT3 D835Y HM43239 hematologic cancer predicted - sensitive detail...
FLT3 exon 14 ins FLT3 F691L HM43239 hematologic cancer predicted - sensitive detail...
FLT3 exon 14 ins FLT3 F621L KW-2449 hematologic cancer resistant detail...
FLT3 exon 14 ins KW-2449 hematologic cancer sensitive detail...
FLT3 exon 14 ins FLT3 A627P KW-2449 hematologic cancer resistant detail...
FLT3 exon 14 ins FLT3 F691L KW-2449 hematologic cancer resistant detail...
FLT3 exon 14 ins FLT3 Y842C KW-2449 hematologic cancer resistant detail...
FLT3 exon 14 ins FLT3 F621L Quizartinib hematologic cancer sensitive detail...
FLT3 exon 14 ins FLT3 A627P Quizartinib hematologic cancer resistant detail...
FLT3 exon 14 ins FLT3 Y842C Quizartinib hematologic cancer resistant detail...
FLT3 exon 14 ins FLT3 A627P Lestaurtinib hematologic cancer resistant detail...
FLT3 exon 14 ins FLT3 A627P Sorafenib hematologic cancer resistant detail...
FLT3 exon 14 ins FLT3 A627P Midostaurin hematologic cancer resistant detail...
FLT3 exon 14 ins FLT3 A627P Sunitinib hematologic cancer resistant detail...
CSF3R T618I Ruxolitinib + Trametinib hematologic cancer sensitive detail...
CSF3R T618I Imatinib hematologic cancer no benefit detail...
CSF3R T618I Trametinib hematologic cancer sensitive detail...
CSF3R T618I Ruxolitinib hematologic cancer sensitive detail...
FLT3 exon 14 ins FLT3 D835Y Dubermatinib hematologic cancer sensitive detail...
FLT3 exon 14 ins FLT3 D835H Dubermatinib hematologic cancer sensitive detail...
FLT3 exon 14 ins Dubermatinib hematologic cancer sensitive detail...
FLT3 exon 14 ins FLT3 F691L Dubermatinib hematologic cancer sensitive detail...
FLT3 D835H Dubermatinib hematologic cancer sensitive detail...
FLT3 D835Y Dubermatinib hematologic cancer sensitive detail...
FLT3 exon 14 ins JAK2 V617F Midostaurin hematologic cancer resistant detail...
FLT3 exon 14 ins JAK2 V617F Ruxolitinib hematologic cancer resistant detail...
FLT3 exon 14 ins JAK2 V617F Gilteritinib hematologic cancer resistant detail...
FLT3 exon 14 ins JAK2 V617F Midostaurin + Ruxolitinib hematologic cancer sensitive detail...
FLT3 exon 14 ins JAK2 V617F Gilteritinib + Ruxolitinib hematologic cancer sensitive detail...
FLT3 exon 14 ins JAK3 V722I Midostaurin + Ruxolitinib hematologic cancer sensitive detail...
FLT3 exon 14 ins JAK3 V722I Gilteritinib + Ruxolitinib hematologic cancer sensitive detail...
FLT3 exon 14 ins JAK3 V722I Midostaurin hematologic cancer resistant detail...
FLT3 exon 14 ins JAK3 V722I Ruxolitinib hematologic cancer resistant detail...
FLT3 exon 14 ins JAK3 V722I Gilteritinib hematologic cancer resistant detail...
FLT3 exon 14 ins JAK3 V722I Tofacitinib hematologic cancer resistant detail...
FLT3 exon 14 ins JAK3 V722I Midostaurin + Tofacitinib hematologic cancer sensitive detail...
FLT3 exon 14 ins JAK2 V617F Tofacitinib hematologic cancer resistant detail...
FLT3 exon 14 ins JAK2 V617F Midostaurin + Tofacitinib hematologic cancer decreased response detail...
FLT3 exon 14 ins JAK3 R953* Midostaurin hematologic cancer sensitive detail...
FLT3 exon 14 ins JAK3 V722I Pacritinib hematologic cancer decreased response detail...
FLT3 exon 14 ins JAK2 V617F Pacritinib hematologic cancer predicted - sensitive detail...
FLT3 exon 14 ins LT-171-861 hematologic cancer sensitive detail...
FLT3 exon 14 ins FLT3 D835Y LT-171-861 hematologic cancer predicted - sensitive detail...
FLT3 D835Y LT-171-861 hematologic cancer sensitive detail...
FLT3 exon 14 ins FLT3 Y842C LT-171-861 hematologic cancer sensitive detail...
FLT3 exon 14 ins FLT3 N676D LT-171-861 hematologic cancer sensitive detail...
FLT3 exon 14 ins FLT3 F691L LT-171-861 hematologic cancer sensitive detail...
JAK2 V617F C220 hematologic cancer predicted - sensitive detail...
FLT3 A680V Gilteritinib hematologic cancer sensitive detail...
FLT3 exon 14 ins KX2-391 hematologic cancer sensitive detail...
FLT3 exon 14 ins FLT3 F691L KX2-391 hematologic cancer sensitive detail...
FLT3 exon 14 ins FLT3 D835Y KX2-391 hematologic cancer sensitive detail...
FLT3 exon 14 ins FLT3 D835V KX2-391 hematologic cancer sensitive detail...
FLT3 exon 14 ins FLT3 D835F KX2-391 hematologic cancer sensitive detail...
FLT3 exon 14 ins FLT3 G697R Quizartinib hematologic cancer resistant detail...
FLT3 exon 14 ins FLT3 G697R Midostaurin hematologic cancer resistant detail...
FLT3 exon 14 ins FLT3 N701K Gilteritinib hematologic cancer resistant detail...
FLT3 exon 14 ins FLT3 C695S FF-10101 hematologic cancer predicted - resistant detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00074490 Phase II Cyclophosphamide Cyclosporine Rituximab Doxorubicin Etoposide Filgrastim Vincristine Sulfate Fludarabine Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers Terminated USA 0
NCT00167180 Phase II Cyclophosphamide + Fludarabine Post Transplant Donor Lymphocyte Infusion Terminated USA 0
NCT00305682 Phase II Sirolimus Mycophenolate mofetil anti-thymocyte globulin Cyclophosphamide Fludarabine Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant Completed USA 0
NCT00520130 Phase Ib/II Cytarabine + Fludarabine Alemtuzumab + Cyclosporine Cyclophosphamide + Doxorubicin + Etoposide + Fludarabine + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Etoposide + Fludarabine + Prednisone + Vincristine Sulfate Methotrexate + Sirolimus + Tacrolimus Filgrastim Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System Completed USA 0
NCT00697632 Phase I Glesatinib Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies Completed USA | CAN 1
NCT01203722 Phase Ib/II Tacrolimus Sirolimus Cyclophosphamide + Fludarabine + Mycophenolate mofetil Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies Recruiting USA 0
NCT01231412 Phase III Sirolimus Fludarabine Cyclosporine + Mycophenolate mofetil Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Completed USA 2
NCT01339871 Phase I Vorinostat Pazopanib Phase I Study of Pazopanib and Vorinostat Completed USA 0
NCT01375842 Phase I Atezolizumab A Phase 1 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors Completed USA 3
NCT01376310 Phase II Docetaxel + Trametinib Erlotinib + Trametinib Trametinib Pemetrexed Disodium + Trametinib Carboplatin + Trametinib Nab-paclitaxel + Trametinib Gemcitabine + Trametinib Everolimus + Trametinib GSK1120212 Rollover Study Terminated USA | CAN 4
NCT01529827 Phase II Melphalan Methotrexate Tacrolimus Mycophenolate mofetil Fludarabine Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed USA 0
NCT01531894 Phase II Afuresertib Continuation Study of the Oral AKT Inhibitor GSK2110183 Completed USA | CAN 3
NCT01619761 Phase I Rituximab Fludarabine + Lenalidomide + Melphalan Mycophenolate mofetil Tacrolimus Natural Killer (NK) Cells in Cord Blood Transplantation Active, not recruiting USA 0
NCT01635712 Phase I SNX-5422 Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies Completed USA 0
NCT01643603 Phase Ib/II Dasatinib Dasatinib in Treating Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant Terminated USA 0
NCT01664910 Phase Ib/II Bendamustine + Fludarabine + Inotuzumab ozogamicin Rituximab anti-thymocyte globulin Tacrolimus CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies Active, not recruiting USA 0
NCT01760655 Phase II Tacrolimus Cyclophosphamide + Fludarabine + Thiotepa Mycophenolate mofetil Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies Recruiting USA 0
NCT01767766 Phase I Umbralisib Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies Completed USA 0
NCT01822509 Phase I Ipilimumab + Nivolumab Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant Completed USA 0
NCT01831726 Phase II Dovitinib Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Completed USA 0
NCT01833169 Phase II Buparlisib BKM120 for Patients With PI3K-activated Tumors Completed USA 0
NCT01885195 Phase II Binimetinib MEK162 for Patients With RAS/RAF/MEK Activated Tumors Completed USA 0
NCT01919619 Phase II Ipilimumab + Lenalidomide Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies Active, not recruiting USA 0
NCT01954316 Phase I CFI-400945 A Study of CFI-400945 Fumarate in Patients With Advanced Cancer Active, not recruiting USA | CAN 0
NCT01981187 Phase II Encorafenib LGX818 for Patients With BRAFV600 Mutated Tumors Terminated USA 0
NCT02002689 Phase II Sonidegib LDE225 for Patients With PTCH1 or SMO Mutated Tumors Terminated USA 0
NCT02065869 Phase Ib/II BPX-501 Rimiducid Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant Active, not recruiting 2
NCT02074839 Phase I Ivosidenib Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation Recruiting USA 1
NCT02076997 Phase I Methotrexate Individualized High Dose Methotrexate to Treat Cancer in Children Who Have a Significant Risk for Side Effects to Methotrexate Completed USA 0
NCT02118311 Phase II Fludarabine Cyclophosphamide T Regulatory Cell for Suppression of Acute Graft-vs-Host-Disease After a Non-Myeloablative Umbilical Cord Blood Transplantation Withdrawn USA 0
NCT02160041 Phase II Infigratinib BGJ398 for Patients With Tumors With FGFR Genetic Alterations Terminated USA 0
NCT02162888 Phase I Bendamustine A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients Completed USA 0
NCT02186821 Phase II Ceritinib Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE) Terminated USA 0
NCT02187783 Phase II Ribociclib LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) Completed USA 0
NCT02223598 Phase I CB-5083 CB-5083 + Dexamethasone A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies (CLC-102) Terminated USA | CAN 0
NCT02272998 Phase II Ponatinib Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT. Recruiting USA 0
NCT02333162 Phase I Mycophenolate mofetil Tacrolimus Fludarabine + Melphalan Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant Recruiting USA 0
NCT02342613 Phase I Activated PTCgamma MILs Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation Recruiting USA 0
NCT02343679 Phase II Ceritinib Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies Withdrawn USA 0
NCT02352558 Phase I Imatinib Napabucasin Bortezomib Ibrutinib Dexamethasone A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies Completed USA 0
NCT02362035 Phase Ib/II Acalabrutinib Pembrolizumab ACP-196 in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies (KEYNOTE145) Active, not recruiting USA 0
NCT02369029 Phase I BAY 1238097 BAY1238097, First in Man Terminated USA 5
NCT02381886 Phase I IDH305 A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations Active, not recruiting USA | CAN 6
NCT02418000 Phase Ib/II E6201 A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 Mutation Terminated USA 0
NCT02419755 Phase II Cytarabine Mercaptopurine Methotrexate Pegaspargase Vorinostat Doxorubicin Bortezomib Dexamethasone Mitoxantrone Prednisone Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies Terminated USA 0
NCT02423915 Phase Ib/II Filgrastim Rituximab Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention Completed USA 0
NCT02452697 Phase II DUK-CPG-001 Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT Recruiting USA 0
NCT02484053 Phase I Rituximab Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders Completed USA 0
NCT02492737 Phase I AG-881 Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation Completed USA 1
NCT02494258 Phase II Azacitidine A Study to Evaluate Long-term Safety in Subjects With Solid Tumors and Hematological Disorders. Active, not recruiting USA 0
NCT02508038 Phase I Zoledronic acid Fludarabine + Melphalan Melphalan Tacrolimus anti-thymocyte globulin Mycophenolate mofetil Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa Recruiting USA 0
NCT02561988 Phase I Avapritinib (EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies Active, not recruiting USA 1
NCT02571036 Phase I Ripretinib A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies Active, not recruiting USA | CAN 4
NCT02576496 Phase I Tinostamustine Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies Recruiting USA 6
NCT02584933 FDA approved Ceritinib Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study Recruiting USA 20
NCT02588105 Phase I Olaparib AZD0156 Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer Active, not recruiting USA 3
NCT02611063 Phase I Fostamatinib Evaluation of Fostamatinib in Patients With cGVHD After Allogeneic Stem Cell Transplant Recruiting USA 0
NCT02612285 Phase II SNX-5422 Study of SNX-5422 in TP53 Null Cancers Terminated USA 0
NCT02639559 Phase II BKT140 Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies Active, not recruiting USA 0
NCT02658890 Phase Ib/II BMS-986205 + Ipilimumab + Nivolumab BMS-986205 + Nivolumab An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread Active, not recruiting USA | CAN 9
NCT02663518 Phase I TTI-621 A Trial of TTI-621 for Patients With Hematologic Malignancies Recruiting USA | CAN 0
NCT02679131 Phase I Belinostat To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment. Terminated USA 0
NCT02680795 Phase I Belinostat To Evaluate the Safety and Pharmacokinetics of Belinostat in Patients Who Have Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes Completed USA 0
NCT02711137 Phase Ib/II INCB057643 A Phase 1/2, Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies Terminated USA 2
NCT02774291 Phase I Aldesleukin Cyclophosphamide + Fludarabine Filgrastim Anti-ESO (Cancer/Test Antigen) mTCR-transduced Autologous Peripheral Blood Lymphocytes and Combination Chemotherapy in Treating Patients With Metastatic Cancer That Expresses NY-ESO-1 Recruiting USA 0
NCT02813135 Phase Ib/II Ribociclib + Temozolomide + Topotecan Adavosertib + Carboplatin Enasidenib Lirilumab + Nivolumab Irinotecan + Olaparib European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors (ESMART) Recruiting 7
NCT02862275 Phase 0 Atezolizumab Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer Recruiting USA | CAN 0
NCT02889445 Expanded access DM-CHOC-PEN A Phase I Trial of DM-CHOC-PEN in Adolescent and Young Adult (AYA) Subjects With Advanced Cancers No longer available USA 0
NCT02921919 Phase II Talazoparib Open-Label Extension and Safety Study of Talazoparib Completed USA | CAN 7
NCT02937675 Phase Ib/II Tomivosertib A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Hematological Malignancies Terminated USA 0
NCT02985554 Phase I Nivolumab Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies Terminated USA 0
NCT03075696 Phase I Obinutuzumab + RO7082859 + Tocilizumab A Dose Escalation Study of RO7082859, Administered After a Fixed, Single Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma Recruiting USA | CAN 11
NCT03151057 Phase I Idelalisib Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies Active, not recruiting USA 0
NCT03219268 Phase I MGD013 A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms Active, not recruiting USA 6
NCT03236857 Phase I Venetoclax A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies Recruiting USA | CAN 6
NCT03263637 Phase I AZD4573 Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies Completed 3
NCT03386513 Phase I IMGN632 Study of IMGN632 in Patients With Relapse/Refractory AML, BPDCN, ALL, Other CD123+ Hem Malignancies Recruiting USA 3
NCT03386526 Phase Ib/II APG-1387 APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies Recruiting USA 0
NCT03420430 Expanded access GL-ONC1 Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care No longer available USA 0
NCT03422679 Phase Ib/II CB-103 Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies Recruiting USA 3
NCT03440437 Phase I FS118 FS118 First in Human Study in Patients With Advanced Malignancies After PD-1/PD-L1 Containing Therapy Recruiting USA 0
NCT03485547 Phase I Venetoclax Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Recruiting USA 0
NCT03512340 Phase I SRF231 Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers Completed USA | CAN 0
NCT03533283 Phase I Obinutuzumab + RO7082859 Obinutuzumab + Polatuzumab vedotin-piiq + RO7082859 + Tocilizumab Atezolizumab + Obinutuzumab + RO7082859 + Tocilizumab An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma Recruiting USA 6
NCT03555955 Phase I CPX-351 A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 Completed USA | CAN 0
NCT03588936 Phase I Nivolumab + Tocilizumab Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant Terminated USA 0
NCT03711604 Phase Ib/II Tenalisib Compassionate Use Study of Tenalisib (RP6530) Enrolling by invitation USA 2
NCT03733249 Phase Ib/II BPX-501 + Rimiducid Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study Enrolling by invitation 2
NCT03739606 Phase II Flotetuzumab Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Withdrawn 0
NCT03837899 Phase Ib/II Durvalumab + Tremelimumab Durvalumab Durvalumab and Tremelimumab for Pediatric Malignancies Recruiting USA 6
NCT03838926 Phase I Trichostatin A Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies Unknown status USA 0
NCT03849651 Phase II TCR alpha/beta+/CD19+ depleted hematopoietic cells CD45RA-depleted donor lymphocytes anti-thymocyte globulin + Cyclophosphamide + Filgrastim + Fludarabine + Melphalan + Mesna + Thiotepa Blinatumomab TCRalphabeta-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies Recruiting USA 0
NCT03850366 Phase II Bortezomib + Cyclophosphamide HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib Recruiting USA 0
NCT04020185 Phase Ib/II IMSA101 + unspecified PD-L1 antibody IMSA101 + unspecified PD-1 antibody IMSA101 Safety and Efficacy Study of IMSA101 in Refractory Malignancies Recruiting USA 0
NCT04077723 Phase I Obinutuzumab + RO7227166 + Tocilizumab Obinutuzumab + RO7082859 + RO7227166 + Tocilizumab A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of RO7227166 in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab Administered in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma Recruiting 7
NCT04130542 Phase I LVGN6051 Phase 1 Trial of LVGN6051 as Single Agent and in Combination Therapy in Advanced or Metastatic Malignancy Recruiting USA 0
NCT04184869 Phase I Belinostat Atazanavir + Belinostat Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials Recruiting USA 0
NCT04216524 Phase II Cyclophosphamide + Dexamethasone + Methotrexate + Rituximab + Venetoclax + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Methotrexate + Rituximab + Venetoclax + Vincristine Sulfate Cyclophosphamide + Dexamethasone + Doxorubicin + Methotrexate + Rituximab + Venetoclax + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Methotrexate + Rituximab + Venetoclax + Vincristine Sulfate Cytarabine + Methotrexate + Methylprednisolone + Rituximab + Venetoclax Tagraxofusp-erzs + Venetoclax Cytarabine + Methotrexate + Rituximab + Venetoclax Tagraxofusp-erzs Mercaptopurine + Methotrexate + Prednisone + Tagraxofusp-erzs + Venetoclax + Vincristine Sulfate Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm Recruiting USA 0
NCT04241835 Phase I Tazemetostat A Study of Oral Tazemetostat in Subjects With Moderate and Severe Hepatic Impairment With Advanced Malignancies Recruiting USA 4
NCT04347226 Phase II BMS-986253 Anti-Interleukin-8 (Anti-IL-8) for Cancer Patients With COVID-19 Recruiting USA 0
NCT04537715 Phase I Itraconazole + Tazemetostat Rifampin + Tazemetostat A Two-part Study to Characterize Drug-Drug Interaction Effects on Steady-State Pharmacokinetics of Oral Tazemetostat Recruiting USA 0
NCT04603001 Phase I LY3410738 Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations Recruiting USA | CAN 9
NCT04605614 Phase I Pembrolizumab 64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression Recruiting USA 0
NCT04681105 Phase I Acetaminophen + Dexamethasone + Diphenhydramine + Flotetuzumab + Ranitidine Dexamethasone + Diphenhydramine + Flotetuzumab + Ibuprofen + Ranitidine Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies Recruiting USA 0
NCT04764474 Phase I HMPL-306 A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH Recruiting USA 0